WuXi PharmaTech, a pharmaceutical, biotechnology, and medical- device research and development services company, with operations in China and the United States, announced that it updated its 2013 financial guidance.
According to a release, the company expects to achieve total revenues for full-year 2013 of approximately $578 million. The company expects diluted EPS for full-year 2013 to slightly exceed the top end of its previous guidance of $1.51-$1.55 (GAAP) and $1.73- $1.77 (non-GAAP). These preliminary 2013 results are unaudited and remain subject to the finalization of the company's year-end closing, reporting, and audit processes. The company plans to report its fourth-quarter and full-year 2013 financial results and to provide 2014 financial guidance in March 2014.
The company also announced that it will present at the 32th annual J.P. Morgan Healthcare Conference on January 15, at 8:30 a.m. Pacific Standard Time. The company's slides from the conference will be available on the company's Investor Relations page.
((Comments on this story may be sent to firstname.lastname@example.org))